Cepheid: 4 Different Insiders Have Sold Shares This Year

Feb. 5.14 | About: CEPHEID (CPHD)

In this article, I will feature one tech stock that has seen intensive insider selling during the last 30 days. Intensive insider selling can be defined by the following three criteria:

  1. The stock was sold by three or more insiders within one month.
  2. The stock was not purchased by any insiders in the month of intensive selling.
  3. At least two sellers decreased their holdings by more than 10%.

Cepheid (NASDAQ:CPHD), a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market; and for application in legacy non-clinical market.

Click to enlarge

Insider selling during the last 30 days

Here is a table of Cepheid's insider-trading activity during the last 30 days by insider.

Name Title Trade Date Shares Sold Rule 10b5-1 Current Ownership Decrease In Ownership
Joseph Smith EVP Jan 16-31 65,000 Yes 11,181 shares 85.3%
Andrew Miller CFO Jan 31 63,375 Yes 4,584 shares + 62,625 options 48.5%
John Bishop CEO Jan 16-31 250,000 Yes

39,176 shares

86.5%
Kerry Flom EVP Jan 16-27 15,889 Yes 20,000 shares + 2,592 options 41.3%
Click to enlarge

There have been 394,264 shares sold by insiders during the last 30 days. All these shares were sold pursuant to a Rule 10b5-1 plan.

SEC Rule 10b5-1 is a regulation enacted by the United States Securities and Exchange Commission (SEC) in 2000. The SEC states that Rule 10b5-1 was enacted in order to resolve an unsettled issue over the definition of insider trading, which is prohibited by SEC Rule 10b-5. After Rule 10b5-1 was enacted, the SEC staff publicly took the position that canceling a planned trade made under the safe harbor does not constitute insider trading, even if the person was aware of the inside information when canceling the trade. This staff interpretation raises the possibility that executives can exploit this safe harbor by entering into 10b5-1 trading plans before they have inside information while retaining the option to later cancel those plans based on inside information.

For example, a CEO of a company could call a broker on January 1 and enter into a plan to sell a particular quantity of shares of his company's stock on March 1, find out terrible news about his company on February 1 that will not become public until April 1, and then go forward with the March 1 sale anyway, saving himself from losing money when the bad news becomes public. Under the terms of Rule 10b5-1(b) this is insider trading because the CEO "was aware" of the inside information when he made the trade. But he can assert an affirmative defense under Rule 10b5-1(c), because he planned the trade before he learned the inside information.

In general, it is a safer way for an insider to sell shares pursuant to a Rule 10b5-1 trading plan than without it.

Insider selling by calendar month

Here is a table of Cepheid's insider-trading activity by calendar month.

Month Insider selling / shares Insider buying / shares
January 2014 403,058 0
December 2013 10,000 0
November 2013 70,141 0
October 2013 43,261 0
September 2013 33,000 0
August 2013 15,629 0
July 2013 3,265 0
June 2013 3,000 0
May 2013 32,300 0
April 2013 137,799 0
March 2013 3,000 0
February 2013 71,964 0
January 2013 9,397 0
Click to enlarge

There have been 835,814 shares sold, and there have been zero shares purchased by insiders since January 2013. The month of January 2014 has seen the most insider selling.

Financials

Cepheid reported the full-year 2013 financial results on January 30 with the following highlights:

Revenue $401.3 million
Net loss $18.0 million
Cash $74.9 million
Debt $1.7 million
Click to enlarge

Outlook

Cepheid's 2014 guidance is as follows:

Revenue $446-$461 million
Net loss -$0.26 to -$0.21 per share
Click to enlarge

Competition

Cepheid's competitors include Becton, Dickinson and Company (NYSE:BDX), and Life Technologies (NASDAQ:LIFE). Here is a table comparing these companies.

Company CPHD BDX LIFE
Market Cap: 3.30B 20.85B 13.14B
Employees: N/A 29,979 10,000
Qtrly Rev Growth (yoy): 0.23 0.05 0.03
Revenue: 401.29M 8.01B 3.84B
Gross Margin: 0.48 0.52 0.66
EBITDA: 7.18M 2.13B 1.20B
Operating Margin: -0.04 0.20 0.21
Net Income: -17.97M 929.00M 476.09M
EPS: -0.27 6.50 2.72
P/E: N/A 16.54 28.00
PEG (5 yr expected): -20.78 1.91 2.30
P/S: 8.48 2.55 3.42
Click to enlarge

Cepheid has the highest P/S ratio among these three companies.

Here is a table of these competitors' insider-trading activities during the last 12 months.

Company Insider buying / shares Insider selling / shares
BDX 0 196,659
LIFE 0 62,010
Click to enlarge

Only Cepheid has seen intensive insider selling during the last 30 days.

Conclusion

There have been four different insiders selling Cepheid, and there have not been any insiders buying Cepheid during the last 30 days. All four of these insiders decreased their holdings by more than 10%. Cepheid has an insider ownership of 0.80%.

Before going short Cepheid, I would like to get a bearish confirmation from the Point and Figure chart. The three main reasons for the proposed short entry are relatively high P/S ratio, negative earnings, and the intensive insider-selling activity.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.